Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 379

1.

Optimized Peptide-MHC Multimer Protocols for Detection and Isolation of Autoimmune T-Cells.

Dolton G, Zervoudi E, Rius C, Wall A, Thomas HL, Fuller A, Yeo L, Legut M, Wheeler S, Attaf M, Chudakov DM, Choy E, Peakman M, Sewell AK.

Front Immunol. 2018 Jun 29;9:1378. doi: 10.3389/fimmu.2018.01378. eCollection 2018.

2.

Using fMRI to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia.

Petzke F, Jensen KB, Kosek E, Choy E, Carville S, Fransson P, Williams SCR, Marcus H, Mainguy Y, Ingvar M, Gracely RH.

Scand J Pain. 2013 Apr 1;4(2):65-74. doi: 10.1016/j.sjpain.2012.10.002.

PMID:
29913906
3.

Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate.

O'Mahony A, John MR, Cho H, Hashizume M, Choy EH.

J Transl Med. 2018 Jun 7;16(1):156. doi: 10.1186/s12967-018-1532-5.

4.

Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.

Schuetze SM, Bolejack V, Thomas DG, von Mehren M, Patel S, Samuels B, Choy E, D'Amato G, Staddon AP, Ganjoo KN, Chow WA, Rushing DA, Forscher CA, Priebat DA, Loeb DM, Chugh R, Okuno S, Reinke DK, Baker LH.

JAMA Oncol. 2018 Jun 1;4(6):814-820. doi: 10.1001/jamaoncol.2018.0601.

PMID:
29710216
5.

CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells.

Liu T, Yan Z, Liu Y, Choy E, Hornicek FJ, Mankin H, Duan Z.

Cell Physiol Biochem. 2018;46(3):1218-1230. doi: 10.1159/000489072. Epub 2018 Apr 16.

6.

Cardiovascular risk factors predicting cardiac events are different in patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis.

Cooksey R, Brophy S, Kennedy J, Gutierrez FF, Pickles T, Davies R, Piguet V, Choy E.

Semin Arthritis Rheum. 2018 Mar 17. pii: S0049-0172(17)30621-2. doi: 10.1016/j.semarthrit.2018.03.005. [Epub ahead of print]

7.

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries.

Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Bernasconi C, Pethö-Schramm A.

Rheumatology (Oxford). 2018 Jun 1;57(6):1129. doi: 10.1093/rheumatology/key116. No abstract available.

8.

Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells.

Chen H, Shen J, Choy E, Hornicek FJ, Shan A, Duan Z.

Oncotarget. 2017 Nov 28;9(17):13154-13166. doi: 10.18632/oncotarget.22743. eCollection 2018 Mar 2.

9.

An evidence-based review of pregabalin for the treatment of fibromyalgia.

Arnold LM, Choy E, Clauw DJ, Oka H, Whalen E, Semel D, Pauer L, Knapp L.

Curr Med Res Opin. 2018 Aug;34(8):1397-1409. doi: 10.1080/03007995.2018.1450743. Epub 2018 Apr 16.

PMID:
29519159
10.

Clinicopathologic characteristics of poorly differentiated chordoma.

Shih AR, Cote GM, Chebib I, Choy E, DeLaney T, Deshpande V, Hornicek FJ, Miao R, Schwab JH, Nielsen GP, Chen YL.

Mod Pathol. 2018 Feb 26. doi: 10.1038/s41379-018-0002-1. [Epub ahead of print]

PMID:
29483606
11.

Secondary Acute Leukemia in Sarcoma Patients: A Population-Based Study.

Sanford NN, Martin AM, Brunner AM, Cote GM, Choy E, DeLaney TF, Aizer AA, Chen YL.

Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):687-694. doi: 10.1016/j.ijrobp.2017.11.011. Epub 2017 Nov 14.

PMID:
29413281
12.

The Impact of Biologics and Tofacitinib on Cardiovascular Risk Factors and Outcomes in Patients with Rheumatic Disease: A Systematic Literature Review.

Nurmohamed M, Choy E, Lula S, Kola B, DeMasi R, Accossato P.

Drug Saf. 2018 May;41(5):473-488. doi: 10.1007/s40264-017-0628-9. Review.

13.

Corrigendum: Synovial tissue research: a state-of-the-art review.

Orr C, Vieira-Sousa E, Boyle DL, Buch MH, Buckley CD, Cañete JD, Catrina AI, Choy EHS, Emery P, Fearon U, Filer A, Gerlag D, Humby F, Isaacs JD, Just SA, Lauwerys BR, Goff BL, Manzo A, McGarry T, McInnes IB, Najm A, Pitzalis C, Pratt A, Smith M, Tak PP, Tas SW, Thurlings R, Fonseca JE, Veale DJ.

Nat Rev Rheumatol. 2017 Dec 19;14(1):60. doi: 10.1038/nrrheum.2017.206.

PMID:
29255214
14.

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries.

Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Bernasconi C, Pethö-Schramm A.

Rheumatology (Oxford). 2018 Mar 1;57(3):499-507. doi: 10.1093/rheumatology/kex443. Erratum in: Rheumatology (Oxford). 2018 Jun 1;57(6):1129.

15.

CDK4 expression in chordoma: A potential therapeutic target.

Liu T, Shen JK, Choy E, Zhang Y, Mankin HJ, Hornicek FJ, Duan Z.

J Orthop Res. 2018 Jun;36(6):1581-1589. doi: 10.1002/jor.23819. Epub 2017 Dec 22.

PMID:
29194728
16.

Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis.

Choy EHS, Calabrese LH.

Rheumatology (Oxford). 2017 Nov 22. doi: 10.1093/rheumatology/kex391. [Epub ahead of print]

PMID:
29186541
17.

Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates.

Lopez G, Braggio D, Zewdu A, Casadei L, Batte K, Bid HK, Koller D, Yu P, Iwenofu OH, Strohecker A, Choy E, Lev D, Pollock R.

PLoS One. 2017 Nov 29;12(11):e0188859. doi: 10.1371/journal.pone.0188859. eCollection 2017.

18.

Are the ACR 2010 diagnostic criteria for fibromyalgia better than the 1990 criteria?

Sarzi-Puttini P, Atzeni F, Masala IF, Salaffi F, Chapman J, Choy E.

Autoimmun Rev. 2018 Jan;17(1):33-35. doi: 10.1016/j.autrev.2017.11.007. Epub 2017 Nov 3. Review.

PMID:
29108831
19.

Synovial tissue research: a state-of-the-art review.

Orr C, Vieira-Sousa E, Boyle DL, Buch MH, Buckley CD, Cañete JD, Catrina AI, Choy EHS, Emery P, Fearon U, Filer A, Gerlag D, Humby F, Isaacs JD, Just SA, Lauwerys BR, Le Goff B, Manzo A, McGarry T, McInnes IB, Najm A, Pitzalis C, Pratt A, Smith M, Tak PP, Thurlings R, Fonseca JE, Veale DJ.

Nat Rev Rheumatol. 2017 Sep 22;13(10):630. doi: 10.1038/nrrheum.2017.161.

PMID:
28935945
20.

Next-Generation Sequencing for Patients with Sarcoma: A Single Center Experience.

Cote GM, He J, Choy E.

Oncologist. 2018 Feb;23(2):234-242. doi: 10.1634/theoncologist.2017-0290. Epub 2017 Aug 31.

PMID:
28860410
21.

The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.

Winthrop KL, Wouters AG, Choy EH, Soma K, Hodge JA, Nduaka CI, Biswas P, Needle E, Passador S, Mojcik CF, Rigby WF.

Arthritis Rheumatol. 2017 Oct;69(10):1969-1977. doi: 10.1002/art.40187. Epub 2017 Sep 6.

22.

Participants' experiences of an Education, self-management and upper extremity eXercise Training for people with Rheumatoid Arthritis programme (EXTRA).

Bearne LM, Manning VL, Choy E, Scott DL, Hurley MV.

Physiotherapy. 2017 Dec;103(4):430-438. doi: 10.1016/j.physio.2016.12.002. Epub 2016 Dec 21.

PMID:
28823567
23.

Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report.

Bartlett SJ, Barbic SP, Bykerk VP, Choy EH, Alten R, Christensen R, den Broeder A, Fautrel B, Furst DE, Guillemin F, Hewlett S, Leong AL, Lyddiatt A, March L, Montie P, Pohl C, Scholte Voshaar M, Woodworth TG, Bingham CO 3rd.

J Rheumatol. 2017 Oct;44(10):1536-1543. doi: 10.3899/jrheum.161145. Epub 2017 Aug 15.

PMID:
28811351
24.

Phase 1 trial of preoperative image guided intensity modulated proton radiation therapy with simultaneously integrated boost to the high risk margin for retroperitoneal sarcomas.

DeLaney TF, Chen YL, Baldini EH, Wang D, Adams J, Hickey SB, Yeap BY, Hahn SM, De Amorim Bernstein K, Nielsen GP, Choy E, Mullen JT, Yoon SS.

Adv Radiat Oncol. 2017 Jan 4;2(1):85-93. doi: 10.1016/j.adro.2016.12.003. eCollection 2017 Jan-Mar.

25.

Therapeutic applications of histone deacetylase inhibitors in sarcoma.

Tang F, Choy E, Tu C, Hornicek F, Duan Z.

Cancer Treat Rev. 2017 Sep;59:33-45. doi: 10.1016/j.ctrv.2017.06.006. Epub 2017 Jul 6. Review.

PMID:
28732326
26.

Synovial tissue research: a state-of-the-art review.

Orr C, Vieira-Sousa E, Boyle DL, Buch MH, Buckley CD, Cañete JD, Catrina AI, Choy EHS, Emery P, Fearon U, Filer A, Gerlag D, Humby F, Isaacs JD, Just SA, Lauwerys BR, Le Goff B, Manzo A, McGarry T, McInnes IB, Najm A, Pitzalis C, Pratt A, Smith M, Tak PP, Thurlings R, Fonseca JE, Veale DJ, Tas SW.

Nat Rev Rheumatol. 2017 Aug;13(8):463-475. doi: 10.1038/nrrheum.2017.115. Epub 2017 Jul 13. Review. Erratum in: Nat Rev Rheumatol. 2017 Sep 22;13(10 ):630. Nat Rev Rheumatol. 2017 Dec 19;14 (1):60.

PMID:
28701760
27.

Application of metabolomics in sarcoma: From biomarkers to therapeutic targets.

Min L, Choy E, Tu C, Hornicek F, Duan Z.

Crit Rev Oncol Hematol. 2017 Aug;116:1-10. doi: 10.1016/j.critrevonc.2017.05.003. Epub 2017 May 13. Review. No abstract available.

PMID:
28693790
28.

Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.

Choy EH, Bernasconi C, Aassi M, Molina JF, Epis OM.

Arthritis Care Res (Hoboken). 2017 Oct;69(10):1484-1494. doi: 10.1002/acr.23303. Epub 2017 Sep 6.

29.

Expression and Therapeutic Potential of SOX9 in Chordoma.

Chen H, Garbutt CC, Spentzos D, Choy E, Hornicek FJ, Duan Z.

Clin Cancer Res. 2017 Sep 1;23(17):5176-5186. doi: 10.1158/1078-0432.CCR-17-0177. Epub 2017 Jun 12.

PMID:
28606919
30.

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.

Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A, Pavelka K, Pablos JL, Rizzo W, Hrycaj P, Zhang N, Shergy W, Kaur P.

Ann Rheum Dis. 2017 Oct;76(10):1679-1687. doi: 10.1136/annrheumdis-2016-210459. Epub 2017 Jun 5.

31.

Localized Adult Ewing Sarcoma: Favorable Outcomes with Alternating Vincristine, Doxorubicin, Cyclophosphamide, and Ifosfamide, Etoposide (VDC/IE)-Based Multimodality Therapy.

Pretz JL, Barysauskas CM, George S, Hornick JL, Raut CP, Chen YE, Marcus KJ, Choy E, Hornicek F, Ready JE, DeLaney TF, Baldini EH.

Oncologist. 2017 Oct;22(10):1265-1270. doi: 10.1634/theoncologist.2016-0463. Epub 2017 May 26.

PMID:
28550026
32.

The pathogenesis of dermatomyositis.

Thompson C, Piguet V, Choy E.

Br J Dermatol. 2017 May 24. doi: 10.1111/bjd.15607. [Epub ahead of print] Review.

PMID:
28542733
33.

Update on Treatment Guideline in Fibromyalgia Syndrome with Focus on Pharmacology.

Kia S, Choy E.

Biomedicines. 2017 May 8;5(2). pii: E20. doi: 10.3390/biomedicines5020020. Review.

34.

Linguistic asymmetry, egocentric anchoring, and sensory modality as factors for the observed association between time and space perception.

Choy EEH, Cheung H.

Cogn Process. 2017 Nov;18(4):479-490. doi: 10.1007/s10339-017-0817-6. Epub 2017 May 17.

PMID:
28516394
35.

An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets.

Hill KE, Kelly AD, Kuijjer ML, Barry W, Rattani A, Garbutt CC, Kissick H, Janeway K, Perez-Atayde A, Goldsmith J, Gebhardt MC, Arredouani MS, Cote G, Hornicek F, Choy E, Duan Z, Quackenbush J, Haibe-Kains B, Spentzos D.

J Hematol Oncol. 2017 May 15;10(1):107. doi: 10.1186/s13045-017-0465-4.

36.

EULAR recommendations for management of fibromyalgia.

Macfarlane GJ, Kronisch C, Atzeni F, Häuser W, Choy EH, Amris K, Branco J, Dincer F, Leino-Arjas P, Longley K, McCarthy G, Makri S, Perrot S, Sarzi Puttini P, Taylor A, Jones GT.

Ann Rheum Dis. 2017 Dec;76(12):e54. doi: 10.1136/annrheumdis-2017-211587. Epub 2017 May 5. No abstract available.

PMID:
28476880
37.

Alterations to adipose tissue morphology during inflammatory arthritis is indicative of vasculopathology in DBA/1 mice.

Sime K, Choy EH, Williams AS.

Adipocyte. 2017 Apr 3;6(2):87-101. doi: 10.1080/21623945.2017.1295174. Epub 2017 Feb 21.

38.

Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.

Liao Y, Chen L, Feng Y, Shen J, Gao Y, Cote G, Choy E, Harmon D, Mankin H, Hornicek F, Duan Z.

Oncotarget. 2017 May 2;8(18):30276-30287. doi: 10.18632/oncotarget.16326.

39.

Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients.

Fleischmann R, van Vollenhoven RF, Vencovský J, Alten R, Davies O, Mountian I, de Longueville M, Carter D, Choy E.

Rheumatol Ther. 2017 Jun;4(1):57-69. doi: 10.1007/s40744-017-0060-8. Epub 2017 Mar 28.

40.

Lower Placebo Responses After Long-Term Exposure to Fibromyalgia Pain.

Kosek E, Rosen A, Carville S, Choy E, Gracely RH, Marcus H, Petzke F, Ingvar M, Jensen KB.

J Pain. 2017 Jul;18(7):835-843. doi: 10.1016/j.jpain.2017.02.434. Epub 2017 Mar 7.

41.

Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.

Liao Y, Sassi S, Halvorsen S, Feng Y, Shen J, Gao Y, Cote G, Choy E, Harmon D, Mankin H, Hornicek F, Duan Z.

Sci Rep. 2017 Mar 6;7:43941. doi: 10.1038/srep43941.

42.

Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss.

Gao Y, Shen J, Choy E, Mankin H, Hornicek F, Duan Z.

Cell Oncol (Dordr). 2017 Jun;40(3):209-218. doi: 10.1007/s13402-017-0316-x. Epub 2017 Feb 27.

PMID:
28243976
43.

Autophagy as a potential target for sarcoma treatment.

Min L, Choy E, Pollock RE, Tu C, Hornicek F, Duan Z.

Biochim Biophys Acta. 2017 Aug;1868(1):40-50. doi: 10.1016/j.bbcan.2017.02.004. Epub 2017 Feb 24. Review.

PMID:
28242349
44.

miR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo.

Duan Z, Gao Y, Shen J, Choy E, Cote G, Harmon D, Bernstein K, Lozano-Calderon S, Mankin H, Hornicek FJ.

Mol Oncol. 2017 Feb;11(2):151-166. doi: 10.1002/1878-0261.12015. Epub 2016 Oct 24.

45.

Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.

Burmester GR, Choy E, Kivitz A, Ogata A, Bao M, Nomura A, Lacey S, Pei J, Reiss W, Pethoe-Schramm A, Mallalieu NL, Wallace T, Michalska M, Birnboeck H, Stubenrauch K, Genovese MC.

Ann Rheum Dis. 2017 Jun;76(6):1078-1085. doi: 10.1136/annrheumdis-2016-210297. Epub 2016 Dec 22.

46.

Updated Outcome and Analysis of Tumor Response in Mobile Spine and Sacral Chordoma Treated With Definitive High-Dose Photon/Proton Radiation Therapy.

Kabolizadeh P, Chen YL, Liebsch N, Hornicek FJ, Schwab JH, Choy E, Rosenthal DI, Niemierko A, DeLaney TF.

Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):254-262. doi: 10.1016/j.ijrobp.2016.10.006. Epub 2016 Oct 13.

PMID:
27986348
47.

Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.

Liu T, Li Z, Zhang Q, De Amorim Bernstein K, Lozano-Calderon S, Choy E, Hornicek FJ, Duan Z.

Oncotarget. 2016 Dec 13;7(50):83502-83513. doi: 10.18632/oncotarget.13148. Review.

48.

Clinical outcomes for patients after surgery and radiation therapy for mesenchymal chondrosarcomas.

De Amorim Bernstein K, Liebsch N, Chen YL, Niemierko A, Schwab JH, Raskin K, Lozano-Calderon SA, Cote G, Harmon DC, Choy E, Haynes A, Mullen J, Hornicek FJ, DeLaney TF.

J Surg Oncol. 2016 Dec;114(8):982-986. doi: 10.1002/jso.24435. Epub 2016 Oct 28.

PMID:
27790706
49.

Preoperative radiation therapy combined with radical surgical resection is associated with a lower rate of local recurrence when treating unifocal, primary retroperitoneal liposarcoma.

Molina G, Hull MA, Chen YL, DeLaney TF, De Amorim Bernstein K, Choy E, Cote G, Harmon DC, Mullen JT, Haynes AB.

J Surg Oncol. 2016 Dec;114(7):814-820. doi: 10.1002/jso.24427. Epub 2016 Sep 16.

PMID:
27634478
50.

Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials.

Tarp S, Furst DE, Dossing A, Østergaard M, Lorenzen T, Hansen MS, Singh JA, Choy EH, Boers M, Suarez-Almazor ME, Kristensen LE, Bliddal H, Christensen R.

Semin Arthritis Rheum. 2017 Jun;46(6):699-708. doi: 10.1016/j.semarthrit.2016.09.003. Epub 2016 Sep 14. Review.

PMID:
27769592

Supplemental Content

Support Center